/
New Advances for NAFLD/NASH New Advances for NAFLD/NASH

New Advances for NAFLD/NASH - PowerPoint Presentation

phoebe-click
phoebe-click . @phoebe-click
Follow
344 views
Uploaded On 2020-01-19

New Advances for NAFLD/NASH - PPT Presentation

New Advances for NAFLDNASH NAFLD A Spectrum of Disease Who Is at Risk for NAFLD and NASH Prevalence of NAFLD in Europe Prevalence of NAFLD and NASH Predicted to Increase in Europe What Is the Burden of NAFLD in Europe ID: 773293

nash nafld patients risk nafld nash risk patients liver cont europe abbreviations hcc patient burden biopsy metabolic ongoing phase

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "New Advances for NAFLD/NASH" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

New Advances for NAFLD/NASH

NAFLD: A Spectrum of Disease

Who Is at Risk for NAFLD and NASH?

Prevalence of NAFLD in Europe

Prevalence of NAFLD and NASH Predicted to Increase in Europe

What Is the Burden of NAFLD in Europe?

Economic and Health Burden of NASH in 5 European Countries: France, Germany, Italy, Spain and UK

Obesity, Metabolic Syndrome, and Alcohol Use: A Triple Threat?

NAFLD and HCC

NAFLD and HCC (cont)

Liver Transplantation for NASH in Europe

Should Patients With NAFLD Be Screened for HCC?

Current Burden of NAFLD-Related Disease Extrahepatic Greater Than Hepatic

NAFLD and Metabolic Syndrome: A Two-Way Street

The NAFLD/NASH Phenotype

Clinical Management Challenges

Identification of Patients at Risk

Risk Stratification of High-Risk Patients

Serum-Based Single Tests for Identifying Patients With NAFLD at Increased Risk for Worse Outcomes

The Camden and Islington NAFLD Pathway

Does Every Patient With Suspected NASH Need a Liver Biopsy?

Does Every Patient With Suspected NASH Need a Liver Biopsy? (cont)

What Does the Liver Biopsy Tell You and Is It Helpful to the Patient?

Treatment and Management Strategies for Improving Cardiovascular Risk

The Proportion of Weight Loss Matters

Are Statins Safe in Patients With NAFLD?

Pharmacologic Treatment of NAFLD and NASH

Current Ongoing Phase 3 Trials for NASH

REGENERATE: Ongoing Phase 3, Double-Blind, PBO-Controlled Study: 18-Month Secondary Analysis

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)